Moreover, the CHK1 inhibitor (CHK1i) prexasertib (10 mg/kg twice daily) also accelerated DNA double-strand breaks and STING activation, subsequently enhancing T-cell recruitment and effector cell function in small cell lung cancer (SCLC) mouse tumors [132]. The gene discussed is STING1; the disease is small cell lung carcinoma.